GlassScriptPhysician profile
Gary M Garner
NPI 1811067762
$2,099.67
in general payments reported to CMS, 2019-2025
22 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 99% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
See the full distribution for Hospice and Palliative Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $100 · 2023: $127 · 2024: $86.87 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,196 · Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Food and Beverage | $674.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,226.60 | 2022-2025 | |
| Daiichi Sankyo INC. | $174.25 | 2022-2025 | Enhertu |
| Edwards Lifesciences Corporation | $128.97 | 2021 | |
| Janssen Biotech, INC. | $68.20 | 2022-2023 | Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $65.10 | 2025 | Imfinzi |
| Array Biopharma INC | $40.53 | 2025 | Tukysa, Mektovi, Braftovi |
| Merck Sharp & Dohme LLC | $39.71 | 2022-2025 | Keytruda |
| Beone Medicines USA, INC. | $34.89 | 2025 | Brukinsa |
| Tactile Systems Technology INC | $32.63 | 2025 | Nimbl, Flexitouch Plus |
| Immunocore Limited | $32.28 | 2025 | Kimmtrak |
| Pfizer INC. | $26.21 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.89 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.19 | 2023 | Eliquis |
| Azurity Pharmaceuticals, INC. | $23.65 | 2025 | Danziten |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $22.83 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $21.26 | 2023 | Xermelo |
| Pharmacosmos Therapeutics INC. | $21.12 | 2024 | Monoferric |
| Genmab U.S., INC. | $18.00 | 2025 | Tivdak |
| Seagen INC. | $17.68 | 2023 | Tukysa |
| Amgen INC. | $16.53 | 2023 | Vectibix, Xgeva, Nplate |
| Blueprint Medicines Corporation | $15.75 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.